Cognition Therapeutics INC

Cognition Therapeutics announced second quarter 2026 financial results, highlighting progress in its dementia with Lewy bodies program and an extended patent for zervimesine.

Cognition Therapeutics reached FDA alignment on a pivotal Phase 3 trial design for zervimesine to treat psychosis in dementia with Lewy bodies.

Cognition Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders, including the election of two Class II directors and the ratification of its independent auditor.

Cognition Therapeutics presented an update on its investigational oral therapy, zervimesine (CT1812), highlighting its potential for treating psychosis in Dementia with Lewy Bodies (DLB) and its ongoing clinical studies.

Cognition Therapeutics announced a productive meeting with the FDA regarding zervimesine for dementia with Lewy bodies psychosis, discussing a path forward for a registrational program.

Cognition Therapeutics reports Q1 2026 financial results, showing reduced net loss and operating expenses, while preparing for a key FDA meeting regarding zervimesine for DLB psychosis.

Cognition Therapeutics reports on its Q2 2026 financial results, highlighting ongoing clinical trial progress for zervimesine while facing continued operational losses and a need for future funding.

Cognition Therapeutics reports a reduced net loss for Q1 2026, driven by lower R&D expenses, while continuing development of its lead drug candidate, zervimesine.

Cognition Therapeutics reported positive Phase 2 data for zervimesine in DLB and GA, alongside a significant capital raise, extending its cash runway into Q2 2027.

Cognition Therapeutics reported a reduced net loss in Q2 2025, highlighted positive Phase 2 clinical data for zervimesine in Alzheimer's and DLB, and secured funding for a DLB expanded access program, despite ongoing liquidity concerns and Nasdaq compliance challenges.

Cognition Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs targeting age-related degenerative diseases.

Cognition Therapeutics reported its Q3 2024 financial results, highlighting progress in clinical trials but also expressing substantial doubt about its ability to continue as a going concern.

Cognition Therapeutics, a clinical-stage biopharmaceutical company, reported its 2025 annual results, highlighting progress in its zervimesine clinical programs for Alzheimer's and Lewy body dementia, while facing continued net losses and capital needs.

Cognition Therapeutics focuses on Alzheimer's and Lewy Body Dementia programs after reporting 2024 results and discontinuing the MAGNIFY study in dry AMD.

Cognition Therapeutics, a clinical-stage biopharmaceutical company, details its financial performance for 2023 and outlines progress in its clinical programs targeting age-related degenerative diseases.

Cognition Therapeutics Inc. reports that Chief Financial Officer John Brendan Doyle acquired 8,567 shares of common stock on May 1, 2026, through a transaction covering tax withholding obligations.

CFO John Brendan Doyle purchased 10,000 shares of Cognition Therapeutics common stock at $1.13 per share.

CEO and President Lisa Ricciardi purchased 9,175 shares of Cognition Therapeutics common stock at $1.10 per share.

Chief Medical Officer Anthony Caggiano acquired 10,000 shares of Cognition Therapeutics common stock at $1.11 per share.

Cognition Therapeutics CEO Lisa Ricciardi reported the vesting of 800,000 restricted stock units and subsequent sales to cover tax obligations.

Cognition Therapeutics' CFO, John Brendan Doyle, reported an acquisition of 200,000 restricted stock units and a subsequent disposition of shares for tax obligations.

Cognition Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026, to vote on director elections and auditor ratification.

Cognition Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.

Cognition Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Cognition Therapeutics has scheduled its annual stockholder meeting for June 7, 2024, and is urging shareholders to vote on key proposals, including the election of directors and ratification of the company's accounting firm.

Cognition Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, to vote on the election of two Class III directors and the ratification of Ernst & Young LLP as its independent auditor.

Bios Equity Partners and affiliated entities report a material decrease in their beneficial ownership percentage of Cognition Therapeutics, Inc. common stock.

Pathstone Family Office, LLC has filed a Schedule 13G indicating zero beneficial ownership of common stock in Cognition Therapeutics Inc.